European Heart Rhythm Association releases the EHRA white book 2016 EP Europace supplement with Biotronik support
EP Europace supplement provides in-depth analysis on increasing atrial fibrillation ablations and CRT use ; highlights continued inequalities in ICD therapy across Europe.
BERLIN, Germany & SOPHIA ANTIPOLIS, France, August 26, 2016 — The European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and EP Europace journal released the supplement to its ninth annual EHRA White Book today, developed in partnership with BIOTRONIK, just ahead of the 2016 ESC Congress in Rome.
The 2016 EP Europace Supplement provides deeper analysis into data presented in the ninth annual EHRA White Book, which collects and distributes information on the yearly number of cardiac rhythm device implantations and catheter ablations in 50 of the 56 ESC member countries. Consistent with the findings of previous editions, the EHRA White Book 2016 found persistent inequalities across ESC countries in access to treatment for cardiac arrhythmias. It found many ESC countries, particularly in eastern Europe and those not on the European continent, fall behind western European countries in the use of implantable cardioverter defibrillators (ICDs) in a number of key arrhythmia treatments.
“Having this data helps us assess how well we’re able to treat groups of patients who may have been underserved in the past,” says 2016 EHRA White Book Coordinator Dr. Pekka Raatikainen, Finland. “We still need to address the disparities between countries in terms of access to all arrhythmia treatments, whether the issues have to do with finances, facilities, manpower or training. One of EHRA’s key goals is to reduce this gap in a number of ways, particularly through training and fellowships.”
The EHRA White Book 2016 also found an increase in the number of ablations for atrial fibrillation and ventricular tachycardia, as well as an increase in cardiac resynchronization therapy (CRT) and the use of insertable cardiac monitors (ICMs), among other findings. “It is particularly encouraging to see evidence that the number of ablations for atrial fibrillation continues to increase,” commented 2016 EHRA White Book Co-coordinator Dr. David O. Arnar, Iceland. “In combination with increasing ICM use, also documented in the EHRA White Book, we can not only treat patients, but monitor them continuously post-ablation to better gauge success rates.”
BIOTRONIK has supported the EHRA White Book through an unrestricted educational grant since the first edition in 2008. “The results of nine years of continued support are clear—a robust body of data shows not just single point inequalities, but real historical developments that can support decision making in various areas,” says Robert Wüstenberg, who leads the EHRA White Book project at BIOTRONIK. “The value of that data increases with every year, so we’re especially looking forward to the tenth edition in 2017.”
About the European Heart Rhythm Association (EHRA)
The European Heart Rhythm Association (EHRA) is a registered branch of the ESC. Its aim is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reducing sudden cardiac death. EHRA promotes science and education in the field of cardiac arrhythmias, with a special focus on atrial fibrillation. Besides patient engagement programmes, EHRA organises scientific and educational events for physicians and allied professionals. In cooperation with other associations and societies EHRA promotes the quality of care for patients with atrial fibrillation through the publication of international consensus documents.
About the European Society of Cardiology (ESC)
The European Society of Cardiology (ESC) brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar, the world’s first 4 F compatible stent for treating long lesions; Orsiro, the industry’s first hybrid drug-eluting stent; and the world’s first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.